Mutational Analysis of Merkel Cell Carcinoma

by Derek J. Erstad, James C. Cusack
Published 2014-10-01

Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.

by Dennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, Isabel Ferreiro-Neira, Taylor Hoff, Zachary A Cooper, Rizwan Haq, David J Panka, Lawrence N Kwong, Michael A Davies, James C Cusack, Keith T Flaherty, David E Fisher, James W Mier, Jennifer A Wargo, Ryan J Sullivan
Published 2014-01-01

Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529

by Devarati Mitra, MD, PhD, Theodore S. Hong, MD, Nora Horick, MS, Brent Rose, MD, Lorraine N. Drapek, NP, Lawrence S. Blaszkowsky, MD, Jill N. Allen, MD, Eunice L. Kwak, MD, PhD, Janet E. Murphy, MD, Jeffrey W. Clark, MD, David P. Ryan, MD, James C. Cusack, MD, Liliana G. Bordeianou, MD, David L. Berger, MD, Jennifer Y. Wo, MD
Published 2017-04-01